In DepthInfectious Diseases

Unusual Ebola vaccine study pays off in Guinea

See allHide authors and affiliations

Science  07 Aug 2015:
Vol. 349, Issue 6248, pp. 569-570
DOI: 10.1126/science.349.6248.569

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

On 31 July, The Lancet published the interim results of a clinical trial in Guinea that showed that an Ebola vaccine produced by Merck appears to be highly effective. The study, organized by the World Health Organization in a consortium with many other agencies, used an unprecedented ring vaccination design, in which the contacts of new Ebola cases as well as the contacts of contacts were vaccinated. The outcome was hailed as a landmark by other scientists, who hope that the vaccine can help to finally end the epidemic in Guinea and Sierra Leone, the two countries that still have Ebola cases.